The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Rapid Response Innovation Awards, 2008MicroRNA regulation of aSynuclein as a drug target
Objective/Rationale:
A central hypothesis for Parkinson’s pathology is that excessive alpha-Synuclein protein, most likely in the form of aggregates, is toxic to midbrain dopamine neurons. Our prior... -
Rapid Response Innovation Awards, 2008Evaluation of a Novel Non-coding Viral RNA to Prevent Neurodegeneration
Objective/Rationale:
Viruses need to keep cells alive during the course of their infection. We recently identified a novel viral RNA which does not code for any known protein but efficiently stops... -
MJFF Research Grant, 2008Wearable Sensors and a Web-Based Application to Monitor Patients with Parkinson's Disease in the Home Environment
Objective/Rationale:
Critical research roadblocks hinder our ability to identify genetic and environmental causes of Parkinson’s disease and to develop novel, transformative therapies for Parkinson’s... -
Target Validation, 2008Evaluation of the striatum-enriched genes, CalDAG-GEF1 and CalDAG-GEF2, as targets for the treatment and prevention of L-DOPA induced dyskinesias
Objective/Rationale:
The most widely prescribed therapy for Parkinson’s disease is levodopa (L-DOPA), which allows patients to regain motor control. However, many patients develop adverse reactions to... -
Target Validation, 2008CaMKII as a Therapeutic Target in Parkinson's Disease
Objective/Rationale:
Neurons in the striatum play a critical role in the fine control of movements. The primary loss of dopamine neurons in Parkinson's Disease induces dramatic secondary changes in the...
-
Target Validation, 2008Hsp90 as a Target for Neuroprotective Agents in Parkinson's Disease
Objective/Rationale:
Cell death caused by alpha-synuclein aggregation is thought to play a central role in the pathogenesis of Parkinson’s disease. Previous studies have found that a class of...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.